Barclays Maintains Overweight on Vor Biopharma, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Vor Biopharma (NASDAQ:VOR) but lowers the price target from $10 to $3.
August 14, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Vor Biopharma but significantly lowers the price target from $10 to $3.
The significant reduction in the price target from $10 to $3 suggests a negative outlook on the stock's potential performance, despite the maintained Overweight rating. This could lead to a short-term decline in the stock price as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100